Mumbai, March 31 -- Innovator Novo Nordisk on Tuesday said it is reducing the starting dose prices for its semaglutide brands Ozempic and Wegovy by 36% and 48%, respectively. It will also offer an average price reduction of 23.8% for Ozempic and 27% for Wegovy across doses. The move comes only weeks after the drugmaker lost patent exclusivity for its type-2 diabetes and weight-loss drug semaglutide on 20 March, triggering an onslaught of cheaper generics in India.

The starting dose for Ozempic and Wegovy (0.25 mg) will be available at Rs.1,415 per week or Rs.5,660 per month under the new pricing, which will come into effect 1 April. Currently, the price of Wegovy is approximately Rs.10,850- Rs.16,400 per month, while that for Ozempic is ...